Beat you to it, Kymriah: Gilead strikes discount Yescarta deal with NHS in adults

5th October 2018 Uncategorised 0

Gilead Sciences has one-upped Novartis in England’s CAR-T market. After a NICE rejection up front, the drugmaker has cut a discount deal with NHS England on Yescarta, beating rival Kymriah to become the first CAR-T therapy available to adult lymphoma patients on England’s public health system, albeit through the Cancer Drugs Fund.

More: Beat you to it, Kymriah: Gilead strikes discount Yescarta deal with NHS in adults
Source: fierce